Idera Pharmaceuticals,Inc. (NASDAQ:IDRA) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.
On March6, 2019,Idera Pharmaceuticals,Inc. (the “Company”) issued a press release announcing the Company’s financial results for the fourth quarter and year ended December31, 2018. As set forth below, the Company is furnishing the press release as Exhibit99.1 to this Current Report on Form8-K.
Item 9.01. Financial Statements and Exhibits.
(a)Financial Statements of Businesses Acquired.
(b)Pro Forma Financial Information.
(c)Shell Company Transactions.
IDERA PHARMACEUTICALS, INC. Exhibit
EX-99.1 2 a19-5969_1ex99d1.htm EX-99.1 Exhibit 99.1 Idera Pharmaceuticals Reports Fourth Quarter and Year End 2018 Financial Results and Provides Corporate Update – ILLUMINATE-301 Enrollment on Track for Completion Q4 2019 – – ILLUMINATE-204 Enrollment Complete; Data Anticipated Q4 2019 – – ILLUMINATE-206 Trial Expected to Initiate Q2 2019 – – Chief Medical Officer Dr. Joanna Horobin Announces Retirement Plan – – Company to Present at Barclays Global Healthcare Conference Next Week – EXTON,…
To view the full exhibit click
About Idera Pharmaceuticals,Inc. (NASDAQ:IDRA)
Idera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor (TLR) targeting technology and third-generation antisense (3GA) technology. Using TLR technology, the Company designs synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. Using its 3GA technology, the Company is developing drug candidates to turn off the messenger ribo nucleic acid (mRNA) associated with disease causing genes. The Company’s drug candidates include IMO-8400; IMO-2125/IMO-2055, and IMO-9200. The Company’s TLR antagonist lead drug candidates are IMO-8400 and IMO-9200, which are both antagonists of TLR7, TLR8 and TLR9. Its TLR agonist lead drug candidates are IMO-2055 and IMO-2125, which are both agonists of TLR9.